Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
enGene Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology issuer focused on non-viral genetic medicines. The company’s SEC reports cover Nasdaq-listed common shares and warrants, emerging growth company status, clinical disclosures for detalimogene voraplasmid and the LEGEND trial, and material agreements tied to financing and operating arrangements.
Recent filings include Form 8-K reports on clinical and financial updates, amendments to a loan and security agreement, an at-the-market sales agreement under a shelf registration statement, executive compensation arrangements, and the completed corporate name change from enGene Holdings Inc. Proxy materials cover annual meeting matters, audited financial statements, director elections, auditor appointment, governance proposals, and shareholder voting procedures.
enGene Holdings Inc. filed a current report noting that it issued a press release on September 30, 2025 announcing the appointment of Dr. Hussein Sweiti as Chief Medical Officer. The press release is furnished, not filed, as Exhibit 99.1 and is not automatically incorporated into other securities filings.